Subcutaneous injection-site reactions reported in the double-blind (DB) period and longterm extension (LTE). Data are n (%) patients with event.
| Reaction Type | DB Period SC ABA + MTX, n = 736 | DB Period IV ABA + MTX, n = 721 | LTE SC ABA + MTX, n = 1372 |
|---|---|---|---|
| Subcutaneous injection-site reaction | 19 (2.6) | 19 (2.6) | 27 (2.0) |
| Erythema | 5 (0.7) | 1 (0.1) | 6 (0.4) |
| Hematoma | 4 (0.5) | 5 (0.7) | 6 (0.4) |
| Pain | 1 (0.1) | 4 (0.5) | 6 (0.4) |
| Unspecified reaction | 1 (0.1) | 3 (0.4) | 4 (0.3) |
| Pruritus | 6 (0.8) | 1 (0.1) | 3 (0.2) |
| Hemorrhage | 0 | 0 | 2 (0.1) |
| Papule | 1 (0.1) | 3 (0.4) | 2 (0.1) |
| Rash | 2 (0.3) | 1 (0.1) | 1 (< 0.1) |
| Other* | 4 (0.5) | 0 | 4 (0.3) |
↵* Other injection-site reactions reported in only 1 patient each included inflammation, nodule, paresthesia, and swelling. Safety data are based on all patients who received at least 1 dose of abatacept in the intent-to-treat population. IV: intravenous; ABA: abatacept; MTX: methotrexate; SC: subcutaneous.